Attitudes toward psychedelics and psychedelic-assisted psychotherapy among Australian mental healthcare providers.

ABSTRACT:

Background

Recent regulatory changes in Australia have approved 3,4-methylenedioxymethamphetamine for treating post-traumatic stress disorder and psilocybin for treatment-resistant depression. However, limited data exists on Australian mental healthcare providers' attitudes, knowledge and readiness to implement with psychedelic-assisted psychotherapy.

Methods

A cross-sectional survey was conducted between December 2023 and March 2024, targeting Australian general practitioners, psychiatrists and psychologists. Participants completed online questionnaires developed based on the Knowledge, Attitude and Practices framework to explore mental healthcare providers' knowledge, attitudes and practices toward psychedelics.

Results

The survey was completed by 109 clinicians (21

SUBMITTER: Nadeem Z 

PROVIDER: S-EPMC12397547 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature